• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
20 results

ACZONE

Docket 207154, Orange Book (Feb. 24, 2016)

cite Cite Docket
Analyze

Letter

Document ACZONE, 207154, Letter (Orange Book Sep. 10, 2019)
listed in the February 24, 2016 approval letter and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Aczone®
the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.
To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with
see the draft guidance for industry Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs.3
If you have any questions, call Strother D. Dixon, Senior Regulatory Project Manager, at
cite Cite Document
Analyze

Label

Document ACZONE, 207154, Label (Orange Book Sep. 10, 2019)

cite Cite Document
Analyze

Label

Document ACZONE, 207154, Label (Orange Book May. 18, 2018)

cite Cite Document
Analyze

Letter

Document ACZONE, 207154, Letter (Orange Book May. 18, 2018)

cite Cite Document
Analyze

Review Pharmacology Reviews

Document ACZONE, 207154, Review Pharmacology Reviews (Orange Book Feb. 24, 2016)

cite Cite Document
Analyze

Review Statistical Reviews

Document ACZONE, 207154, Review Statistical Reviews (Orange Book Feb. 24, 2016)

cite Cite Document
Analyze

Review Administrative Documents & Correspondence

Document ACZONE, 207154, Review Administrative Documents & Correspondence (Orange Book Feb. 24, 2016)

cite Cite Document
Analyze
1 2 >>